inositol has been researched along with Nephrosis, Lipoid in 1 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Nephrosis, Lipoid: A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an in vitro FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR." | 5.51 | Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis. ( An, JN; Cho, JH; Choi, YW; Ha, H; Hwang, GS; Hyeon, JS; Jung, Y; Kim, DK; Kim, JH; Kwon, S; Lee, JP; Lee, SH; Oh, S; Park, SH; Yang, SH, 2019) |
| "Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an in vitro FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR." | 1.51 | Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis. ( An, JN; Cho, JH; Choi, YW; Ha, H; Hwang, GS; Hyeon, JS; Jung, Y; Kim, DK; Kim, JH; Kwon, S; Lee, JP; Lee, SH; Oh, S; Park, SH; Yang, SH, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, JN | 1 |
| Hyeon, JS | 1 |
| Jung, Y | 1 |
| Choi, YW | 1 |
| Kim, JH | 1 |
| Yang, SH | 1 |
| Oh, S | 1 |
| Kwon, S | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Park, SH | 1 |
| Ha, H | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Hwang, GS | 1 |
1 other study available for inositol and Nephrosis, Lipoid
| Article | Year |
|---|---|
Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
Topics: Adult; Aged; Biomarkers; Cell Line; Female; Glomerular Filtration Rate; Glomerulosclerosis, Focal Se | 2019 |